home page
इंस्टीट्यूट ऑफ गुड मैन्यूफैक्चरिंग प्रैक्टिसेज इंडिया
Institute of Good Manufacturing Practices India

(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)

ADMISSIONS NOTICE
18001031071 (Toll Free), Phone: +91 11 26512850
Regular Classroom | Online Mode

Clinical Research

Grifols registers positive topline outcomes from phase 3 fibrinogen clinical tr
Grifols registers positive topline outcomes from phase 3 fibrinogen clinical tr
Beacon registers positive 12-month data from phase 2 SKYLINE trial of AGTC-501 in patients with X-linked retinitis pigmentosa
Beacon registers positive 12-month data from phase 2 SKYLINE trial of AGTC-501 in patients with X-linked retinitis pigmentosa
Chugai Pharma’s mosunetuzumab accomplishes the primary endpoint in expansion cohort of the Japanese phase I trial for r/r follicular lymphoma
Chugai Pharma’s mosunetuzumab accomplishes the primary endpoint in expansion cohort of the Japanese phase I trial for r/r follicular lymphoma
AstraZeneca’s Tagrisso exhibited overwhelming efficacy benefit for patients with unresectable, stage III EGFR-mutated lung cancer in LAURA phase III trial
AstraZeneca’s Tagrisso exhibited overwhelming efficacy benefit for patients with unresectable, stage III EGFR-mutated lung cancer in LAURA phase III trial
Grifols documents positive topline outcomes from the phase 3 fibrinogen clinical trial
Grifols documents positive topline outcomes from the phase 3 fibrinogen clinical trial
Tharimmune’s buccal film liver drug exhibits efficacy in Phase I trial
Tharimmune’s buccal film liver drug exhibits efficacy in Phase I trial
Sanofi and Denali’s ALS therapy misses preliminary endpoint in Phase II trials
Sanofi and Denali’s ALS therapy misses preliminary endpoint in Phase II trials
Phase III thyroid eye disease trial of Innovent fulfils primary endpoint
Phase III thyroid eye disease trial of Innovent fulfils primary endpoint
Sanofi communicates positive results from trial of frexalimab for multiple sclerosis (MS)
Sanofi communicates positive results from trial of frexalimab for multiple sclerosis (MS)
UroMems declares positive results for stress urinary incontinence implant
UroMems declares positive results for stress urinary incontinence implant
Hemab notifies positive Phase I Glanzmann thrombasthenia therapy data
Hemab notifies positive Phase I Glanzmann thrombasthenia therapy data
NeuroSense expands data in Phase IIb ALS study with positive update
NeuroSense expands data in Phase IIb ALS study with positive update
ViiV Healthcare demonstrates positive findings from the phase I study of cabotegravir long-acting injectable investigational formulation
ViiV Healthcare demonstrates positive findings from the phase I study of cabotegravir long-acting injectable investigational formulation
Novartis proposes positive data from the SMART study of Zolgensma in older and heavier children with SMA at the 2024 MDA conference
Novartis proposes positive data from the SMART study of Zolgensma in older and heavier children with SMA at the 2024 MDA conference
CASI and BioInvent declare positive data from lymphoma treatment trial
CASI and BioInvent declare positive data from lymphoma treatment trial